Researchers Identify Chemical Trigger for Brain Inflammation in Alzheimer's Disease
Similar Articles
Experimental Compounds Show Promise in Reducing Brain Inflammation Linked to Alzheimer's
Researchers Identify Brain Cell Process That Removes Alzheimer's Plaques in Mice
CBD Treatment Reduces Brain Inflammation in Mouse Model of Alzheimer's Disease
Researchers Identify New Enzyme Target That Reduces Alzheimer's Plaques in Lab Studies
Arginine Shows Promise in Reducing Alzheimer's Plaques in Animal Studies
Scientists have discovered a specific chemical change that pushes the brain's immune defense system into a damaging, overactive state in Alzheimer's disease. This change, called S-nitrosylation, occurs on a key immune protein called STING and drives chronic inflammation that harms brain cell connections. The finding, published in Cell Chemical Biology, points to a potential new therapeutic target for the disease.
Facts First
- A chemical change called S-nitrosylation (SNO) forces the immune protein STING into overdrive, triggering harmful brain inflammation.
- High levels of this modified SNO-STING protein were found in brain tissue from Alzheimer's patients, as well as in lab-grown cells and mouse models of the disease.
- Protein clumps linked to Alzheimer's, aging, and environmental factors like pollution can initiate this damaging cycle of inflammation and chemical modification.
- Blocking the specific site of this change protected brain connections in mice, reducing inflammation and preventing synapse deterioration.
- Researchers are now developing drug-like molecules to block this mechanism for future preclinical studies.
What Happened
Researchers at Scripps Research identified a molecular mechanism that explains how the brain's immune response becomes chronically activated in Alzheimer's disease. The study focuses on a protein called STING, part of the body's early warning system. The team found that in Alzheimer's, STING undergoes a chemical modification called S-nitrosylation, which causes STING proteins to cluster and activate excessive inflammatory responses. The team detected high levels of this modified SNO-STING in postmortem brain tissue from people with Alzheimer's disease, in human brain immune cells, and in a mouse model of the disease.
Why this Matters to You
This discovery moves science closer to understanding a core driver of brain cell damage in Alzheimer's. While any treatment based on this finding is years away, identifying a specific, targetable mechanism like SNO-STING provides a clearer path for future drug development. For families affected by neurodegenerative diseases, this represents a tangible step toward therapies that could one day slow or prevent the progression of symptoms by calming harmful brain inflammation.
What's Next
The research team has already engineered a version of the STING protein that cannot be modified at the key site, which protected synapses from deterioration in a mouse model. They are now developing small molecules designed to block the cysteine 148 site on STING for future preclinical studies. This work may lead to new classes of drugs that could interrupt the cycle of inflammation and damage in Alzheimer's and potentially other diseases linked to S-nitrosylation, such as Parkinson's.